Nulbia (Lidocaine, Prilocaine)

Lidocaine, the active ingredient in Nulbia, is a local anesthetic presented as a cream for topical use. It provides reversible loss of sensation to the skin, facilitating minor procedures and relieving superficial pain. GNH USA supplies Nulbia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nulbia is a topical local anesthetic used on the skin and superficial lesions. - Minor skin procedures: provides rapid, reversible numbness to facilitate incisions, suturing, or biopsies. - Superficial skin lesions: reduces pain associated with burns, abrasions, or dermatitis. - Dermatologic interventions: eases discomfort during laser therapy, cryotherapy, or chemical peels.

Topical application of Nulbia may be associated with several adverse reactions.

Common Side Effects: - Mild skin irritation: redness, itching, or burning at the application site. - Localized edema: slight swelling where the product is applied. - Transient numbness: prolonged sensation loss beyond the intended period.

Serious or Rare Side Effects: - Allergic reaction: urticaria, angioedema, or anaphylaxis requiring immediate medical attention. - Methemoglobinemia: bluish discoloration of skin or mucous membranes, especially with extensive use. - Systemic toxicity: dizziness, seizures, or cardiac arrhythmias if absorbed in large amounts.

When using Nulbia, consider the following safety measures. - Application area: limit to intact skin and avoid mucous membranes. - Quantity: use only the amount prescribed to reduce systemic absorption. - Age restrictions: avoid use in infants and young children unless directed by a clinician. - Concomitant anesthetics: do not combine with other topical anesthetics to prevent cumulative toxicity. - Allergies: screen for known hypersensitivity to lidocaine, prilocaine, or formulation excipients. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nulbia may interact with other substances that affect sodium channel function or systemic absorption.

Major Interactions (Avoid): - Systemic local anesthetics: concurrent use can increase risk of toxicity. - CYP450 inhibitors: may alter metabolism of lidocaine, raising plasma levels.

Moderate Interactions (Monitor Closely): - Vasoconstrictors (e.g., epinephrine): can modify local blood flow and drug absorption. - Certain antiarrhythmic agents: may potentiate cardiac effects if systemic absorption occurs. - Alcohol or CNS depressants: may enhance central nervous system depression in case of overdose.